Zhixiang Jintai (688443.SH) announcement, today the company received the "Pharmaceutical Registration Certificate" issued by the State Drug Administration, approving the company's independently developed class 1 new drug called Silike monoclonal antibody injection (trade name: Jinlixi) for the treatment of moderate to severe plaque psoriasis indications.
According to the announcement from Zhixiang Jintai (688443.SH), today the company received the "Pharmaceutical Registration Certificate" issued by the State Drug Administration, approving the company's independently developed class 1 new drug called Silike monoclonal antibody injection (trade name: Jinlixi) for the treatment of moderate to severe plaque psoriasis indications.
It is reported that Silike monoclonal antibody injection is the company's first approved product and is expected to have a positive impact on the company's business performance.